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Objective To evaluate infectious complications and antibiotic use in 192 renal transplant recipients.
Methods Infectious complications and antibiotic use were monitored in all patients receiving renal
transplantation at our center from 1992 to 1997. Risk factors for infectious complications were evaluated.
Transplants and patient survival were monitored. The follow-up period was 1 year.
Results One-hundred and ninety-two patients received renal transplants during the study period. The mean
duration of urethral catheterisation after transplantation was 10.5 days (SD¼ 5). Seventy-one per cent
(n¼ 137) of patients had at least one infectious episode. In all, 284 infectious episodes were monitored. The
most frequent infections were: urinary tract infections 61%, respiratory tract infections 8%, intra-abdominal
infections 7%, and cytomegalovirus infection 8%. Escherichia coli and Enterococcus faecalis were the most
frequently isolated microorganisms. Seventy-four per cent (n¼ 142) of patients received 314 antimicrobial
courses (284 for therapy, and 30 for prophylaxis). Female gender and duration of urethral catheterisation
were risk factors for urinary tract infection. Cytomegalovirus reactivation was associated with acute
graft rejection and additional immunosuppressive therapy. Overall mortality was 4%. Infection-related
mortality was 2.6%. Mortality was associated with Enterobacteriaceae in three patients, with Pseudomonas
aeroginosa in one patient and with Enterococcus faecalis in one patient.
Conclusions The incidence of infectious complications remains high in renal transplant recipients. Most cases
of mortality were associated with infections. Early removal of the urethral catheter to reduce the risk of
urinary tract infections is recommended.
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INTRODUCTION
Recipients of renal transplants are prone to develop infections
because of the surgical procedure, immunosuppression, expo-
sure to nosocomial pathogens, and the necessity for devices such
as urinary catheters and intravascular lines in the first days post-
transplantation [1]. Despite improvements of immunosuppres-
sive therapy and surgical techniques, infections remain an
important complication and have been associated with
increased morbidity and graft rejection [2]. Urinary tract
infections (UTIs) following transplantation are associated with
tissue invasion by pathogens. This process might be strengthen
by allograft rejection. The need for urethral catheterisation
during the first days after transplantation, to protect the surgical
anastomosis, represents an important risk for UTI [3–7]. How-
ever, the optimum duration for urethral catheterisation is
unknown [8].
In addition to infection-related morbidity, infections may
initiate allograft rejection, and have been associated with
reactivation of latent cytomegalovirus (CMV) infection [9–11].
For all these reasons, prevention of infection in the early
period after transplantation is important. Early removal of
urethral catheters and the use of antibiotic prophylaxis have
been advocated to reduce infectious complications [3–5]. In our
center, renal transplant recipients receive a short regimen of
antibiotic prophylaxis, and the urethral catheter is usually
removed after 1 week. To assess the impact of the current policy
in our center, we evaluated infectious complications and anti-
biotic use during 1-year follow-up after renal transplantation in
192 patients.
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PATIENTS AND METHODS
Study population
All patients receiving renal transplantation at the University
Hospital Maastricht, The Netherlands, between January 1992
and January 1997, were studied prospectively for a 1-year
period. During this period, all infectious episodes (both noso-
comial and community-acquired infections), antibiotic use,
transplant function, transplant survival and patient survival were
monitored. The CMV serologic status of patients and donors
was determined by measuring IgG antibodies to CMVusing an
ELISA method.
Immunosuppression and surgical procedure
One-hundred and fifty-six patients received prednisone
(10 mg/day, and 5 mg/day after 6 months), azathioprine
(1.5 mg/kg/day, oral) and cyclosporine (initially dosed to a
serum level of 0.1–0.15 mg/L, and to 0.05–0.1 mg/L after
6 months) for immunosuppression. Thirty-six patients received
azathioprine, prednisone, and tacrolimus (FK 506) (0.3 mg/kg/
day, oral). Acute rejection was initially treated with three doses
of 1 g of methylprednisolone on alternating days, and steroid-
resistant episodes were treated with rabbit antithymocyte
globulin (ATG) (initially 3 mg/kg/day, and then dosed on
lymphocyte counts for 10 days).
The kidney graft was placed retroperitoneally in the right or
left iliac fossa. The ureter was anastomosed to the recipient’s
bladder. The recipient’s diseased kidney was not removed.
Perioperative antibiotic prophylaxis and postoperative care
All patients received a 1-day course of intravenous cefuroxime
for antibiotic prophylaxis. The first dose (750 mg) was admini-
strated preoperatively, and the second and third doses were
administered 8 and 16 h postoperatively. Patients did not receive
prophylactic agents for CMV and Pneumocystis carinii. Urine
cultures were obtained twice a week during the hospital stay and
whenever infection was presumed. The urinary catheter was
usually removed after 1 week. After discharge from hospital,
patients were regularly seen at the outpatient clinic, and, when
indicated, cultures and other diagnostic measures were per-
formed. No routine investigations were done for CMV and
tuberculosis infection.
Definitions
The term infectious episode was used to indicate every
episode of presumed or proved infection in which antibiotic
therapy was initiated [12]. Six groups of infectious diseases
were distinguished: UTIs, respiratory tract infections (RTIs),
intra-abdominal infections, CMV infections, wound infections,
and a group of miscellaneous infections.
Although the presence of bacteriuria would fulfill the criteria
for UTI in renal transplant recipients [13], other criteria, such as
pyuria (>10 leukocytes/mm3) and fever, are frequently used for
diagnosing UTI. In the present study, the CDC criteria, e.g. the
clinical judgment of the physician in initiating therapy, was used
as a definition for infection [12]. UTI was considered to be
catheter related if the infection occurred during urethral cathe-
terisation or within 24 h after catheter removal. RTIs were
diagnosed according to the CDC criteria [12]. Intra-abdominal
infectious episodes included local or generalised peritonitis,
abdominal abscess formation, cholangitis, and pancreatitis.
Wound infection was defined as the presence of purulent
discharge from a surgical wound. CMV reactivation was defined
by antigen detection or isolation of virus from any tissue or
body fluid. The diagnosis of CMV disease was based on the
presence of clinical symptoms (fever, malaise, arthralgias, myal-
gias and organ involvement) and detection of CMV in clinical
samples (such as blood and bronchoalveolar lavage fluid).
Data analysis
Data were analyzed by the chi-square or Fisher exact test for
dichotomous variables and the student’s t-test for continuous
variables. Odds ratio and 95% confidence intervals were calcu-
lated with SPSS-software (SPSS Inc., Chicago, IL, USA) as an
estimate of the relative risk.
RESULTS
Patient population
The study population consisted of 192 renal transplant recipi-
ents (121 males and 71 females), with a mean age of 48 years
(range, 17–73 years). Follow-up was complete for all patients for
1 year or until death if this occurred within the first year
following transplantation. Twenty-eight patients (15%) received
transplants from living donors, and the remaining 164 patients
(85%) from non-living donors. Thirty-three patients (17%)
received their second transplant, nine (5%) patients the third
transplant, and two patients (0.5%) the fourth and the fifth
transplant. The most frequent underlying causes of renal failure
were chronic glomerulonephritis (n¼ 47), polycystic kidneys
(n¼ 28), renal failure due to pyelonephritis (n¼ 22), nephro-
sclerosis (n¼ 12), IgA nephropathy (n¼ 12), diabetic nephro-
pathy (n¼ 9), and other renal diseases (n¼ 62). The mean
post-transplant hospitalisation time was 33 days (range 8–97).
Infectious complications
Seventy-one per cent (n¼ 137) of all patients had at least one
infectious episode, with a mean of 1.5 episodes per recipient and
2.0 episodes per infected patient. In all, 284 infectious episodes
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were monitored, and 146 (51%) occurred during hospital stay
after transplantation.
Bacterial infections
Bacteria were considered the cause of infection in 249 (88%) of
284 episodes. Fifty-nine per cent (n¼ 146) of bacterial infec-
tious episodes occurred during hospital stay after transplantation
(Figure 1). Bacterial infectious episodes included: 173 episodes
of UTI, 23 episodes of RTI, 21 intra-abdominal infections, six
wound infections, and 26 unlabeled infection episodes. No
infectious episodes with Nocardia and Listeria were monitored in
the study population.
All wound infectious episodes and 71% (15/21) of intra-
abdominal infectious episodes occurred during hospitalisation
after transplantation. The incidence of wound infections was
3% (n¼ 6), and all episodes were superficial surgical wound
infections that were treated with drainage and antibiotic
therapy. Microbiological cultures of the surgical wounds
revealed Staphylococcus aureus (n¼ 3) and Gram-negative rods
(n¼ 3).
Nine intra-abdominal infectious episodes were surgery
related. Nine intraperitoneal infections were associated with
continuous ambulatory peritoneal dialysis. Three patients
developed cholecystitis and had negative blood cultures.
During the 1-year follow-up, 103 recipients suffered 177
episodes of UTI (173 bacterial episodes and four fungal epi-
sodes). Fifty-six patients suffered one episode of UTI, and 47
patients had recurrent UTI. Overall incidences of UTI were
45% (87/192) during hospital stay after transplantation, and
54% (103/192) during 1-year follow-up. The incidence of UTI
was higher in females than in males: 70% and 42%, respectively
(P< 0.0001). The incidences of bacteriuria in diabetic patients
and patients with polycystic kidneys were 67% (6/9) and 50%
(14/28), respectively.
Escherichia coli and Enterococcus faecalis were the most
frequently isolated microorganisms (Table 1). No methicillin-
resistant Staphylococcus aureus or vancomycin-resistant entero-
cocci were isolated.
Fifty-two (47%) of 111 UTI episodes that occurred during
hospital stay after transplantation were catheter related. The
mean duration of urethral catheterisation was 10.5 days
(SD¼ 5). Patients who suffered an episode of UTI postopera-
tively had longer duration of urethral catheterisation than those
who did not develop UTI: 11.1 days (SD¼ 5) and 9.5 days
(SD¼ 2.7), respectively (P¼ 0.05). Incidences of UTI were
2.6 episodes per 100 catheter-days and 1.4 episodes per
100 days without catheter, respectively (P¼ 0.05). Also, female
gender was associated with occurrence of UTI during
hospital stay after transplantation: 63% of females (n¼ 45/71)
versus 35% of males (n¼ 42/121), P< 0.001. Other variables
such as age, recurrent transplantation, cadaver kidney, diabetes
mellitus and seropositivity to CMV were not associated with
UTI. UTI was not associated with prolonged hospital stay
(P¼ 0.5).
Most episodes of UTI were associated with bacteriuria
(n¼ 147, 83%). Fifty-three episodes were asymptomatic bac-
teriuria. One hundred episodes were associated with pyuria (in
15 episodes, pyuria was the only present criterion). Only five
episodes of UTI (3%) were associated with bacteremia. In 15
episodes, laboratory and microbiological criteria were absent,
and UTI was presumed because of fever and by exclusion of
other infections, such as RTI and intra-abdominal infection. In
85 (48%) episodes, both bacteriuria and pyuria were present
(Figure 2).
Fungal infections
Eight episodes of fungal infection occurred (four episodes of
UTI, three episodes of Pneumocystis carinii pneumonia, and one
episode of oropharyngeal candidiasis). None of the patients had
invasive fungal disease. Candida albicans was the causative patho-
gen in four cases, and Candida species in one episode. The five
patients with candida infection were treated successfully with
fluconazole 200 mg/day for 7 days. Three recipients developed
Pneumocystis carinii pneumonia, all after hospital discharge,
between day 60 and day 193 after transplantation. All three
were treated successfully with co-trimoxazole 960 mg every 8 h
for 2 weeks.
Viral infections
Eighty-five recipients were CMV seropositive, and 107 reci-
pients were seronegative. Twenty-four patients (13%) devel-
oped a clinical episode of CMV infection (eight were recipient
negative (R–) and donor negative (D–), 11 were RþD–, two
were RþDþ, and three were R–Dþ), occurring after a mean of
57 days after transplantation (range 23–199 days). Thirteen of
the 24 CMV infectious episodes were considered to be reacti-
vation. Eleven episodes were considered to be primary CMV
infection. Patients with acute graft rejection had CMV reacti-
vation more frequently than patients without allograft rejection:
20% (16/79) and 7% (8/113), respectively, odds ratio 2.9 (95%
CI 1.3–6.4). In 16 of the 24 patients, CMV infection followed
allograft rejection and increased immunosuppressive treatment
(13 received methylprednisolone and three received methyl-
prednisolone and ATG). One patient had severe infection
(sepsis with Escherichia coli) before rejection occurred. All
patients with CMV infection were treated with a 10-day course
of ganciclovir.
Two patients developed herpes zoster infection (7–10 months
post-transplantation), and one patient developed herpes simplex
stomatitis (39 days post-transplantation). All three patients were
treated with acyclovir for 10 days.
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Use of antimicrobial agents
Overall, 142 (74%) of the 192 patients received 314 courses of
antimicrobial treatment during follow-up; 284 for therapeutic
purposes and 30 for prophylaxis.
In all, 137 patients received 284 courses of antimicro-
bial therapy for suspected or proved infections; 249 cases of
bacterial infection, 27 cases of viral infection, and eight cases of
fungal infection. In 271 (95%) of these courses, a single anti-
microbial agent was prescribed, whereas two agents (b-lactam
antibiotic and aminoglycoside) were prescribed in the remain-
ing 13 (5%) courses.
Amoxicillin–clavulanic acid (n¼ 96), ciprofloxacin (n¼ 47),
amoxicillin (n¼ 39) and ganciclovir (n¼ 24) were used most
frequently. The mean duration of antimicrobial therapy was
14 days (range 1–99 days).
Antimicrobial agents were used in 33% of the postoperative
hospitalisation-days and in 3.8% of all patient-days during
1-year follow-up. Fifty-six per cent of the courses were
prescribed during hospital stay after transplantation.
Twenty-six patients received 30 courses of antibiotics for
prophylaxis. In eight patients, isoniazid was prescribed because
of a positive tuberculin test or history of tuberculosis. In 20
patients, a single dose of co-trimoxazole was given before
removal of the urethral catheter, because the patients had
UTI some days before catheter removal. Two patients received
prophylaxis (ciprofloxacin) for several weeks because of
recurrent episodes of UTI.
Rejection, graft failure and patient survival
Acute rejection occurred in 79 (41%) patients. All were treated
initially with methylprednisolone, and 17 of them needed
additional treatment with ATG. Anti-CMV prophylaxis was
not given to patients with corticosteroid-resistant rejection. An
association was found between rejection and CMV infection.
Additional immunosuppression (16 patients) due to rejection
predisposes to CMV reactivation, odds ratio 2.9 (95% CI 1.3–
6.4). UTI was not associated with allograft rejection (P¼ 0.9) or
allograft survival (P¼ 0.3).
Transplantation failed within hours in eight patients because
of graft thrombosis. Twenty-nine (15%) renal grafts failed
during 1-year follow-up. Overall mortality was 4% (n¼ 8).
These eight patients had experienced at least one infectious
episode. Infection-related mortality was 2.6% (n¼ 5). Of these
Table1 Bacteria and fungi found in the study population
Urinary tract infections Intra-abdominal infections Other infections
Microorganisms
Urine
culture
Blood
culture
CAPD
catheter
Abdominal
pus
Other
specimensa
Blood
culture
Gram-negative bacteria
Escherichia coli 65 2 2 2 4 1
Klebsiella pneumonia 14 ^ 1 2 1 ^
Other Enterobacteriaceae 22 2 ^ ^ 2 ^
Pseudomonas aeruginosa 12 1 2 1 3 ^
Haemophilus influenzae ^ ^ ^ ^ 2 ^
Stenotrophomonas maltophilia 1 ^ ^ ^ ^ ^
Gram-positive bacteria
Staphylococcus aureus 1 ^ 4 4 2 1
Enterococcus faecalis 45 ^ ^ ^ 2 ^
Staphylococcus epidermidis 6 ^ ^ ^ 2 1
Streptococci ^ ^ ^ ^ 1 1
Anaerobes ^ ^ ^ ^ ^ 1
Yeasts
Candida species 4 ^ ^ ^ 1 ^
Pneumocystis carinii ^ ^ ^ ^ 3 ^
aOther specimens include sputum, bronchoalveolar lavage fluid and intravascular devices.
Figure 2 Bacteruria, pyuria and fever in episodes of urinary tract infection.
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five patients, three developed sepsis and multi-organ failure, one
had peritonitis, and one had intra-abdominal abscess. Mortality
was associated with Enterobacteriaceae in three patients, with
Pseudomonas aeroginosa in one patient, and with Enterococcus
faecalis in one patient. Death occurred 55–95 days after
transplantation (mean 80 days).
DISCUSSION
This study shows a high incidence of infectious complications in
renal transplant recipients during a 1-year follow-up after
transplantation. The occurrence of UTI was associated with
the duration of urethral catheterisation and female gender.
CMV reactivation was associated with acute allograft rejection.
A shorter duration of catheterisation could be an important
measure to reduce UTI and antibiotic use in renal transplant
recipients. A urethral catheter is needed after transplantation for
maintaining urine drainage, and to prevent early obstruction,
urinary leaks and vesical fistulas [7]. It has been demonstrated
that the duration of urethral catheterisation is the most impor-
tant risk factor for UTI, and advantages of early removal of the
catheter have been emphasised [3–5,14]. Catheter removal after
8.2 days (SD 3.8) was associated with an incidence of UTI of
74% [4], whereas catheter removal within 36 h was associated
with an incidence of 8% [3]. Ramsey et al. have shown that
catheter removal within 48 h after transplantation reduces the
UTI rate from 17% to 5.6% [14]. The duration of urethral
catheterisation varies considerably in renal transplantation cen-
ters in Europe, but the duration is less than 1 week in 84% of
these centers [8]. In our center, the duration of urethral
catheterisation was long and was associated with the occurrence
of UTI. Prolonged catheterisation is not indicated. The urethral
catheter can be removed within the first week following
transplantation [3–5].
Infection-related mediation of cytokines may trigger CMV
replication [9,15]. However, in the present study, no association
was found between severe infection and CMV reactivation.
Only one patient developed CMV infection following severe
infection. CMV reactivation was associated with acute allograft
rejection and additional immunosuppressive therapy. A link
between infection and allograft rejection has been suggested
[16]. Immunosuppression, acute rejection and urosepsis may
cause cytokine-mediated CMV reactivation. Conversely, CMV
infection may induce cytokine release and subsequently cause
allograft injury [16]. Whether asymptomatic CMV replication
contributes to allograft injury remains unclear [16].
The importance of controlling antibiotic use and preventing
the emergence of resistant microorganisms has been emphasised
[16]. Our results show that antibiotic therapy was frequently
initiated if bacteriuria was present, and severe infections were
infrequently found. This suggests a low threshold for physicians
to start antibiotic treatment. UTI seems not to increase hospital
stay and graft failure. Therefore, we doubt the need to treat
asymptomatic bacteriuria. A shorter duration of urethral
catheterisation postoperatively may reduce the incidence of
bacteriuria and subsequently the use of antibiotics.
High rates of wound infection after renal transplantation,
despite perioperative antimicrobial prophylaxis, were reported
in studies performed in the 1970s and 1980s [17,18]. The
incidence of wound infection was low in the present study,
as in other recent studies [19,20]. However, even without
systemic perioperative prophylaxis, but only local antibiotic
irrigation, the reported incidence of wound infection was only
2% in one study [21], suggesting that the lower incidences of
wound infection in recent years may be partly due to improve-
ments in surgical transplant techniques [21].
Infectious complications, especially UTI, remain a major
cause of morbidity in renal transplant recipients, and lead to
extensive use of antibiotics. Early removal of urethral catheters
and efforts to optimise antimicrobial use are recommended.
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